Get started
Work

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

Year: 2015
Type: article
Abstract: Meeting abstracts Patients with R/M SCCHN have a poor prognosis, and current therapies used after failure of first-line platinum-based chemotherapy provide transient, limited benefit. SCCHN tumors are highly immunosuppressive and evade immune detection by exploiting inhibitory immune checkpoints
DOI: 10.1186/2051-1426-3-s2-p150
Authors: Robert L Ferris, Caroline Even, Robert Haddad, Makoto Tahara, Trishna Goswami, April Franks, Ugochi Emeribe, Anthony Jarkowski, Giovanni Melillo, Lisa Licitra
Institutions: UPMC Hillman Cancer Center, Institut Gustave Roussy, Dana-Farber Cancer Institute, National Cancer Center Hospital East, AstraZeneca (United Kingdom), Fondazione IRCCS Istituto Nazionale dei Tumori
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W2197990531
FWCI: 0.874
Cites:
Cited by: 22
Related to: 10